Company Overview
Snapshot
Founded in January 2018 by Prof. David (Dedi) Meiri and Shmuel (Muli) Mandel, Cannasoul Analytics operates with 11–50 employees. The company has raised $4 million across two funding rounds. In November 2023, Synaptogenix acquired a significant stake in the company, marking a key strategic development.
Business overview
Cannasoul Analytics is an Israeli drug-discovery company focused on developing therapeutics derived from natural cannabis compounds. The company leverages a proprietary analytical platform and a data-driven approach, along with its clinical trial framework, to identify and develop active compounds. It has analyzed over 100 cannabinoids and 100 terpenes, serving the health tech and life sciences sectors, particularly in pharmaceuticals, medical cannabis, and biotechnology.
Strategic signal
In November 2025, InterCure and Cannasoul Analytics signed strategic investment and collaboration agreements to advance cannabis science and pharmaceutical innovation. This partnership signals a significant validation of Cannasoul's drug discovery capabilities and its potential to drive further advancements in the medical cannabis industry, indicating strong forward momentum for investors.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant strategic development for Cannasoul Analytics in late 2023?
- In November 2023, Synaptogenix acquired a significant stake in Cannasoul Analytics, co-founded by The Technion - Israel Institute of Technology. This acquisition highlights external validation of Cannasoul's research and development efforts.
- What strategic agreements did Cannasoul Analytics sign in November 2025?
- In November 2025, Cannasoul Analytics signed strategic investment and collaboration agreements with InterCure. These agreements are aimed at advancing cannabis science and pharmaceutical innovation.
- When did Cannasoul Analytics enter a joint venture with Kensana Health?
- In March 2019, Cannasoul Analytics entered a joint venture with Kensana Health (formerly PRM Inc.).
- What collaboration did Cannasoul Analytics undertake with Eybna in April 2020?
- In April 2020, Cannasoul Analytics joined forces with Eybna, another cannabis R&D firm, to prove a proprietary terpene formulation for treating viral infections by modulating cytokine storm.
- Who are the co-founders of Cannasoul Analytics?
- Cannasoul Analytics was co-founded by Prof. David (Dedi) Meiri, who serves as CSO & Chairman, and Shmuel (Muli) Mandel, who is the CEO.